Humira Star Still Shines Bright In Abbott’s Sky, Despite Tough Economy
Executive Summary
Sales of Abbott's multi-faceted biologic Humira seem to be going from strength to strength, unencumbered by the economic turmoil even though it's an expensive biologic in highly competitive markets
You may also be interested in...
Bayer claims Abbott’s Humira infringes its patent
Bayer filed suit against Abbott Dec. 24 alleging that Humira (adalimumab) infringes its patent covering a composition of human monoclonal antibodies which bind to human tumor necrosis factor alpha. Bayer said the patent, No. 5,654,407, which was issued in 1997, does not cover a specific Bayer drug. Humira, a blockbuster autoimmune therapy, had worldwide sales of $3.1 billion in 2007 and is projected to generate $4.4 billion in sales for 2008 (1"The Pink Sheet," Oct. 20, 2008, p. 5). The complaint, filed in the U.S. District Court for the Eastern District of Texas, requests a jury trial and a finding of willful infringement. Abbott said Humira does not infringe Bayer's patent and that it believes the patent is invalid
Bayer claims Abbott’s Humira infringes its patent
Bayer filed suit against Abbott Dec. 24 alleging that Humira (adalimumab) infringes its patent covering a composition of human monoclonal antibodies which bind to human tumor necrosis factor alpha. Bayer said the patent, No. 5,654,407, which was issued in 1997, does not cover a specific Bayer drug. Humira, a blockbuster autoimmune therapy, had worldwide sales of $3.1 billion in 2007 and is projected to generate $4.4 billion in sales for 2008 (1"The Pink Sheet," Oct. 20, 2008, p. 5). The complaint, filed in the U.S. District Court for the Eastern District of Texas, requests a jury trial and a finding of willful infringement. Abbott said Humira does not infringe Bayer's patent and that it believes the patent is invalid
Market Snapshot: Anti-TNFs Grow Despite Tough Market
At least one class of therapies - anti-tumor necrosis factors - is booming, even in the midst of one of the worst years financially for the pharmaceutical industry